

NEW!
Learning Lab

These important clinical trials are expected to influence practice when they are ultimately reported and/or published.

Top Surgical Videos: Innovations in Diagnostics and Techniques

1-3 p.m.
AUA Square: Learning Lab

Flip the Script: Case Submissions

3-4 p.m.
AUA Square: Learning Lab

AUA Robotics Theater

Don't miss today's moderated session with live narration of robotic procedure videos and a panel discussion.

Supported by Intuitive

Prostate Procedures

9:30-11:30 a.m.
S&T Hall, Booth #2425

Reconstructive Procedures

2-4 p.m.
S&T Hall, Booth #2425

Patient Perspectives

This engaging program aims to help physicians and healthcare providers understand what success looks like in patient-physician communication and shared decision-making.

1-4 p.m.
The Square

A new frontier of immunotherapy for bladder cancer

Anktiva plus BCG works by activating natural killer cells to recognize and eliminate cancer cells that have evaded the immune system.

N-803, also known as nongapendekin alfa inbakicept, or Anktiva, with BCG is a new standard of care for patients with non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) who have failed Bacillus Calmette-Guerin (BCG) and other therapies.

Anktiva received Breakthrough Therapy Designation and approval from the FDA on April 22, 2024, based on interim safety, efficacy and complete response and duration of complete response data from QUILT 3032, an open-label, three-cohort, multicenter phase 2/3 study, with a cutoff of Nov. 30, 2023. The interleukin-15 immunotherapy plus BCG helps harness the natural power of the immune system to attack bladder cancer, leading to a long-term duration of complete response that, for some patients, exceeds 47 months. Patients' tumor status will continue to be assessed with cystoscopy and urine cytology for up to five years.

"Median duration is yet to be determined, and



Patrick Soon-Shiong, MD

duration is everything," said Patrick Soon-Shiong, MD, executive chair, global chief scientific and medical officer of ImmunityBio. On Friday afternoon, Dr. Soon-Shiong spoke with Sam Chang, MD, MBA, the Patricia and Rodes Hart Endowed professor of urological surgery and oncology and the chief surgical officer at Vanderbilt University Medical Center, during an engaging conversation in the Learning Lab about the new FDA approval of Anktiva and the next generation of immunotherapy for NMIBC.

"Anktiva not only proliferates and activates the patient's own natural killer cells and CD8+ killer T cells, but it

activates CD4+ T helper cells to enhance the proliferation of memory killer T cells, to mount 'a triangle offense' against bladder cancer," Dr. Soon-Shiong said. "With Anktiva, we have found a way to reactivate natural killer cells, turning cold tumors that have learned to evade the immune system into hot tumors that respond to therapy," he said.

"The FDA's approval of Anktiva marks the launch of a next-generation immunotherapy beyond checkpoint inhibitors," Dr. Soon-Shiong said. Anktiva is expected to be available in the U.S. momentarily. ImmunityBio has its own U.S.-based large-scale facilities that

will produce both Anktiva and BCG, with special distributors "up and ready."

Anktiva will be available to all patients who need it. "I'm most proud of our patient assistance program, which will limit copays to \$100 and provide the drug for free for patients without insurance who can't afford it," Dr. Soon-Shiong said.

Anktiva plus BCG for patients with NMIBC CIS is only the beginning. In development are studies investigating Anktiva plus BCG for all tumor types and the promise of the first cancer prevention vaccine for patients with Lynch syndrome, which carries an 80% chance of developing colon cancer. ●

INSIDE

WHICH IS THE BEST DIVERSION: CONDUIT OR NEOBLADDER? **3** NEW GUIDELINE FOR PROSTATE CANCER **6** CLINICAL TRIALS IN BENIGN DISEASE **8** PHOTO GALLERY **9** QUESTION OF THE DAY **14**

Focal One[®]
ROBOTIC FOCAL HIFU

SCAN FOR BOOTH SCHEDULE AND VIEW EXPERT SPEAKERS
Booth #409 | FocalOne.com






Jelmyto[®]
(mitomycin) for pyelocalyceal solution

EXTENDING EXPECTATIONS

Experience
the power of
possibilities at
the UroGen[®]
booth.

Learn more about this innovative treatment at
Jelmyto.com/hcp



JELMYTO[®] and UroGen[®] are registered trademarks of UroGen Pharma, Ltd.
© 2024 UroGen Pharma, Inc. All rights reserved. US-JEL-00872 03/24

Which is the best diversion: conduit or neobladder?

Friday's debate featured the pros and cons of both types of urinary diversion to help inform true shared decision-making with your patients.

Continent bladder replacement (neobladders) was developed and widely used beginning in the mid-1980s. Many institutions across the United States and internationally began offering this type of diversion to half or more of their patients undergoing cystectomy, and many published series show long-term safety, patient satisfaction and overall good functional results. Yet nearly 90% of patients undergoing cystectomy will have a standard ileal conduit diversion with a stoma requiring an external bag. Should neobladder diversion be recommended to more patients in lieu of ileal conduit?

Friday's "Crossfire: Controversies in Urology: Ileal Conduit vs. Neobladder: 68-Year-Old Man Who Wants a Neobladder but Is Unsure About Catheterizing," debated the rationale for recommending a neobladder or a standard ileal conduit for an index patient, a healthy 68-year-old man with a recent diagnosis of muscle-invasive bladder cancer but without medical contraindications, who theoretically asks, "Which type of diversion is best for me?"

"There are only a few real medical contraindications to a neobladder," said session moderator Eila C. Skinner, MD, chair of the department of urology and professor of urology at Stanford

University in California. "Every urologist who does cystectomies says they let their patient decide what type of diversion they want. But, in fact, it's easy to steer patients to what you want to do."

Anne Schuckman, MD, associate professor of urologic oncology at the Keck USC School of Medicine in Los Angeles, presented evidence highlighting the perioperative safety of neobladder surgery and the low rates of complications, such as incontinence, urinary retention and infections.

"Up to 25% of patients experience early complications for all diversions, but neobladder infections stabilize over time," she said. Conversely, the complication rates of ileal conduits increase slowly over time. "Many patients are willing to accept short-term risks for a long-term payoff," Dr. Schuckman said.

Mark Tyson, MD, MPH, associate professor of urology at the Mayo Clinic in Phoenix, reviewed quality-of-life literature that supports patient satisfaction with neobladder reconstruction. "When adjusted for age, neobladders result in better quality of life for younger, fitter patients," he said. With a neobladder, patients appreciate improved general health, the ability to more easily use public bathrooms and a better body image.



Joshua Meeks, MD, PhD

Joshua Meeks, MD, PhD, professor of urology at Northwestern University in Chicago, argued that there is limited data on the long-term burdens of neobladders. "The neobladder is probably not the best choice for patients with bladder cancer," he said. "What happens if these patients have a recurrence of their cancer? When patients have complications, the neobladder makes it so much harder. What if more treatment is needed?"

Amy N. Luckenbaugh, MD, assistant professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee, outlined the

benefits of an ileal conduit, including lower operative time and lower length of stay, fewer postoperative complications and readmissions, improved simplicity of care and maintenance, and equivalent quality-of-life outcomes. Overall, "humans are adaptable. They will learn to live with whatever you throw at them," she said.

AUA Guidelines endorse a fair discussion of all forms of urinary diversion. "Both types of diversion have acceptable outcomes, and the choice should reflect the patient's own values and priorities," Dr. Skinner said. ●

AUA 2024SM San Antonio **DAILY NEWS**

The AUA Daily News is the official newspaper of AUA2024 and is published by Ascend Media.

AUA Staff
 Darci Berliant
 Heather Corkin
 Elaine Garrison
 Melissa Goodman
 Scott D. Morrow
 Katie Phipps
 Jennifer Regala
 Kathleen Warshawsky

Ascend Media
 Cindy Ratcliff, Editor & Writer
 Timothy Nord, Senior Graphic Designer

© 2024 American Urological Association
 1000 Corporate Blvd.
 Linthicum, MD 21090
 www.auanet.org

Ascend Media encourages and practices environmentally friendly printing, including recycled/recyclable paper and plant-based inks.

American Urological Association

AUA JobFinder

CAREER FAIR
 Sunday, May 5
 10 a.m. – 12 p.m.
 Street Level near the West Lobby

Take the next step in your career! Meet with 35 companies hiring in urology!

HEALTH eCAREERS™

Registration is encouraged.

Scan the QR code for a preview of today's session, "How to prevent and manage nightmare cases in urology."

PLUVICTO can be the next step on your patient's treatment journey

Reimagine what's possible at

Booth 1555



Scan here for more information about PLUVICTO



Merck Medical Forums

Join us for a Product Theater

Merck cordially invites you to attend the medical education event listed below for US healthcare professionals and US healthcare business professionals only. Merck is sponsoring this event and the speakers are presenting on behalf of Merck. The events are non-CME programs. Information presented in this event is consistent with FDA guidelines.



Actor Portrayals.

Title: A Treatment Approach for Certain Patients With High-risk, Non-muscle Invasive Bladder Cancer

Learning objectives:

- Review the cases of hypothetical patients with high-risk, non-muscle invasive bladder cancer (NMIBC)
- Present efficacy and safety data for a treatment option for certain patients with high-risk NMIBC
- Understand how to monitor and manage potential select adverse reactions

Speaker: Vahan Kassabian, MD



Dr. Vahan Kassabian is a urologic oncologist with Advanced Urology serving as the Director of the Atlanta Prostate Center and Advanced Therapeutics in Atlanta, GA. Dr. Kassabian earned his M.D. and completed his residency at the University of Montreal followed by fellowship training in urologic oncology at Baylor College of Medicine in Houston, Texas. He is a former Assistant Professor, Department of Surgery at Emory University and also served as Chief of Urology at the V.A. Hospital in Atlanta. His clinical research interests include general urologic oncology and he is a contributing editor to *Reviews in Urology*. His research has been featured in articles, abstracts and chapters of leading academic publications. Dr. Kassabian is an international speaker and has lectured extensively on prostate cancer and disease. He is a member of the American Urological Association, the American College of Surgeons and the Society of Urological Oncology.

Sunday, May 5, 2024

1:00 PM - 2:00 PM CT

Henry B. González Convention Center

Hemisfair Ballroom 1

Merck Medical Forums are educational meetings and do not include alcoholic beverages.



Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. US-NON-15666 04/24

New guideline for prostate cancer introduced at AUA2024

The new Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline (2024) was unveiled during the morning Plenary on Friday. This is not a revision or an update of the prior 2013 guideline; rather, it is a new consensus document built from the ground up, said Guideline Committee Chair Todd Morgan, MD, chief of urologic oncology and the Jack Lapides, MD, Research Professor at the University of Michigan in Ann Arbor.

“There has been a huge number of new trials in this area in the past 10 years,” Dr. Morgan said. “The science and evidence around prostate cancer and salvage therapy for prostate cancer have advanced dramatically since the last guideline on adjuvant and salvage radiotherapy after prostatectomy was published. We had no recourse to PET imaging and molecular markers five years ago, and molecular markers play an important

role in the new guideline we developed with ASTRO (American Society for Radiation Oncology) and SUO (Society of Urologic Oncology).”

The guideline focuses on management recommendations for patients with biochemical recurrence (BCR) following prostatectomy or other curative treatment. Trials have brought new recommendations for the timing and delivery of salvage therapy, risk stratification, use of ADT, quality of life, molecular imaging and metastasis-directed therapy.

The 2013 guideline, for example, recommended offering salvage therapy to patients with BCR, noting that earlier is better. However, it was not possible to provide guidance on the potential use of androgen deprivation therapy due to lack of data.

Most patients should now receive salvage radiation therapy (RT) when PSA is still ≤ 0.5 ng/mL. Patients at high risk for clinical progression can start RT when PSA is < 0.2 ng/mL.

Advanced imaging is now standard of care. When considering salvage RT for BCR following prostatectomy, the new guideline states that clinicians should perform next-generation molecular PET imaging.

There is also a call for ADT in addition to salvage RT after prostatectomy for patients with BCR and any high-risk features. RT alone may be appropriate for patients without high-risk features.


Patients with no evidence of metastatic disease who are candidates for local salvage therapy should have a prostate biopsy before treatment. For patients with biopsy-documented recurrence, clinicians should offer prostatectomy, cryoablation, high intensity focused ultrasound or re-irradiation as part of a shared decision-making approach.

“We will undoubtedly see updates with continued refinement of adjuvant systemic therapy with RT and improved understanding







Todd Morgan, MD

of how PSMA PET should be used in treatment decisions in the BCR setting,” Dr. Morgan said, “and we can appreciate that the results of EMBARK (enzalutamide plus leuprolide in nonmetastatic prostate cancer) will be incorporated.” ●



VISIT
AUA2024
BOOTH
#170

**Family of Single use
Neo-Nephroscopes & Vortex-Dual
lumenAccess sheath for Mini-PCNL**

408.483.5474
309 Piercy Rd - San Jose, CA - USA
Neoscope2020.com

AQUA&Census

CELEBRATING
10 YEARS

Attend the Data Symposium: 10 Years of Census and AQUA Data

Saturday, May 4, 2024 | 4-6 p.m.
Video Abstract Theater

Celebrate and reflect on the past, present,
and future data-driven initiatives using the
AQUA and Census data.



Stay up to date with INLYTA[®] (axitinib) + pembrolizumab data

To learn more, visit our booth



*Scan to visit the
Virtual Booth*



*Scan to see the full
Prescribing Information*

Key clinical trials take center stage at AUA2024

Clinical Trials in Progress, “Benign Disease” opened on Friday afternoon with a glimpse at a new sheath for nephrolithiasis. “Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy with Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis” compares a novel sheath that allows surgeons to irrigate and suction simultaneously. Based on the mini-PCNL, pilot study showed greater stone-free rate, less operative time, lower intrarenal pressure, and fewer complications compared to conventional sheaths.

“We have enrolled 20% of our target of 90 patients,” reported Sri Silvalingam, MD, Glickman Urological and Kidney Institute, Cleveland Clinic Foundation, “but it is too early to have data to report.”

RELIEF, the “Reduced-dose onabotulinumtoxinA for Urgency Incontinence Among Older Females” compares 50 IU injections of Botox into the detrusor muscle vs the standard 100 IU in older women with urge incontinence. Quality of life is the primary outcome, secondary outcomes include comparisons of clinical and patient-reported outcomes.

“Patients are often concerned about cost, we clinicians are concerned about side effects,” said E. Ann Gormley, Professor of Urology Surgery, Dartmouth Hitchcock Clinic. “RELIEF addresses both concerns.”

Enrollment opened in May, 2023 with 174 patient as of April, and will

close April, 2025 at 376.

Multiple observational trials suggest that exercise improves outcomes for older men with urinary disease, but there are few randomized controlled trials. The “Prescription exercise for Older men with Urinary Disease (PROUD) trial” is comparing the effect of receiving exercise information on exercise vs. information plus active exercise coaching. Endpoints include the rate and intensity of physical exercise plus patient-reported and clinical changes in body measurements, lab measurements, and urologic function.

PROUD is targeting 68 participants, said Stacey A. Kenfield, SM, ScD, Professor and Epidemiology & Biostatistics, University of California, San Francisco, and is actively seeking partners for a multi-center trial.

“We have a real shortage of randomized controlled data,” Dr. Kenfield said. “We have our first 15 patients, so if you have patients in the community who might be appropriate, please refer them!”

AUA guidelines recommend stent omission after uncomplicated ureteroscopy, yet 80% of U.S. ureteroscopy patients are stented. A 2019 Cochrane Review article noted that stenting may slightly reduce the number of unplanned visits.

“The Cochrane data are uncertain,” said Khurshid Ghani, MBChB, MS, FRCS, University of Michigan Urological Surgery Improvement Collaborative “We need a good randomized clinical trial.”

“Stent Omission after Ureteroscopy



Sri Sivalingam, MD

and Lithotripsy (SOUL)” is a patient-centered comparative effectiveness trial of stent vs. no stent following uncomplicated ureteroscopy. The trial has recruited 50 of a planned 125 patients for the 2-year, 14 center trial. Patients who want to participate but are not willing to undergo randomization can enroll in an observational arm, a first in this population. Dr. Ghani said SOUL results are expected to guide surgical practice nationally.

Other trials are exploring the benefits of treating small, asymptomatic stones in the office, using hydration to prevent urinary stones, holmium-YAG vs Thulium fiber laser for dusting stones, and investigational drug to block bladder pain, and multiple new treatments for erectile dysfunction. ●



Stacey A. Kenfield, SM, ScD

PRODUCT SPOTLIGHT

neoscope

Neo-Ureteroscope +
Vortex System



408.483.5474
309 Piercy Rd - San Jose, CA

Neoscope2020.com

VISIT
AUA2024
BOOTH
#170

mediplus

Mediplus S-Cath™ System

Safer, more precise
suprapubic catheterization

The Seldinger
suprapubic
catheter
insertion kit

www.s-cath.com



New!



KEY TAKEAWAYS

MONDAY, MAY 6 | 12-3 P.M.

Join us Monday afternoon as we showcase highlights from the 2024 AUA Annual Meeting. In this innovative new format, thought leaders take the stage for a series of discussions that review the most impactful science from AUA2024. Key Takeaways will be in the Main Lobby, where attendees can grab lunch, connect with colleagues, and hear AUA2024 highlights and take-home messages by topic area.



Giddyup! AUA2024 rides into town



Merck Medical Forums

Join us for a Product Theater

Merck cordially invites you to attend the medical education event listed below for US healthcare professionals and US healthcare business professionals only. Merck is sponsoring this event and the speakers are presenting on behalf of Merck. The events are non-CME programs. Information presented in this event is consistent with FDA guidelines.



Title: Patient Case-Based Learning: Clinical Management of Certain Patients With VHL Disease

Learning objectives:

- Understand von Hippel-Lindau (VHL) disease through a hypothetical patient case
- Review clinical data on a management option for certain patients with VHL disease
- Discuss monitoring and management of potential adverse reactions through a patient case

Saturday, May 4, 2024

10:15 AM - 11:00 AM CT

Henry B. González Convention Center

S&T Hall, Booth #1159

Speaker: Brian Shuch, MD

Title: A Treatment Option for Certain Patients With Renal Cell Carcinoma in the Adjuvant Setting

Learning objectives:

- Review renal cell carcinoma (RCC)
- Understand clinical data supporting a treatment option for certain patients with RCC in adjuvant treatment setting
- Understand how to monitor and manage potential adverse reactions associated with this treatment option

Sunday, May 5, 2024

12:00 PM -12:45 PM CT

Henry B. González Convention Center

S&T Hall, Booth #1159

Speaker: Vahan Kassabian, MD

Merck Medical Forums are educational meetings and do not include alcoholic beverages.



Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-NON-15666 04/24



Lithotripsy



Single-use



Reusable



Stone Devices



Confidence in Every Approach

Being ready for every stone requires confidence in yourself and trust in the equipment you use.

Olympus provides you with the solutions you need to approach every stone and to address the unique anatomy and pathology of a wide range of patients.



Visit Olympus Booth #311

For more information, scan the QR code

For safe and proper of Olympus devices follow the manufacturer's instructions for use handling, operating, and reprocessing of each product. If used or handled in an improper manner, there is a risk of patient and/or operator injuries, burns, infections, bleeding, and/or perforation, and/or equipment damage.



Food Court

S&T SCIENCE & TECHNOLOGY HALL MAP AND EXHIBITOR LIST

Exhibitor list and map current as of 04/11/2024

Residents Pavilion

Product Theater

History Booth

Device Tech Talk

Entrance

Square Entrance (Primary)

Square Entrance



The Square

Premier Exposuites

ExpoSuite 5	ExpoSuite 6
ExpoSuite 3	ExpoSuite 4
ExpoSuite 8	ExpoSuite 7

A&E Endoscopy 1226
 A.M.I. Agency for Medical Innovations GmbH 148
 AbbVie 243
 Accord BioPharma 1051
 AcuityMD 874
 Advance Medical Designs 923
 AdventHealth 2826
 AED 869
 Agiliti 768
 Akumin, Inc. 271
 Akumin, Inc. 273
 ALDAVER Co., Ltd. 1563
 Alnylam Pharmaceuticals 1168
 Ambu Inc. 2572
 Ambu Inc. 809
 America Medic & Science, AMS 143
 AMNOTEK International Medical GmbH 1017
 Amplify Lab Solutions 173
 Andromeda Surgical 2322
 AngioDynamics 653
 Angiogenesis Analytics BV 2353
 APEX Biologix 2930
 Applaud Medical, Inc. 2459
 Ardent Health Services 2250
 Artesia General Hospital 2827
 Ascend Therapeutics 2050
 Asociación Urológica de Centroamerica y Caribe (AUCA) 1066

ASSI-Accurate Surgical & Scientific Inst. 1123
 Astellas Pharma US 1543
 AstraZeneca 1505, 2961, 2962
 Avenda Health 2443
 Axonics, Inc. 1623
 Ballard Health Medical Associates 2352
 Barrigel 1225
 Bastion Health 2932
 Bayer 1342, 1959
 BD 1517, 2163
 BDSC Company 979
 Benefis Health System 2835
 Best Medical International 1843
 Billings Clinic 2453
 Bioprotect 2550, 2565, 2664
 Biote 1952
 BK Medical/GE HealthCare 1451, 2465

Blue Earth Diagnostics, Inc. 1605
 BlueWind Medical 1705, 2670
 BoldRx Corporation 1950
 Boston Scientific 431, 2271, 2370, 2372
 Bostwick Laboratories a Division of PathAI Diagnostics 1922
 Bot Image, Inc. 2849
 Bright Uro 2957
 Bristol Myers Squibb - Commercial 253, 2667
 Bronson Health 1651
 Caldera Medical 2364
 Caldera Medical 958
 Calmoseptine, Inc. 2055
 Calyxo, Inc. 843
 Canadian Urological Association (CUA) 670
 CAREstream America 2942
 CareTech Human Inc. 1659

Case Recruiters, Inc 569
 Ceevra Inc 2648
 CG Oncology Inc. 100
 CHRISTUS Health 2650
 CirrusDx 2834
 CIVCO Medical Solutions 2123
 Clarius Mobile Health 1063
 Clear Guide Medical 2926
 Cleveland Clinic 122
 Cohealo 2651
 Colegio Mexicano de Urología Nacional, A. C. 1064
 Coloplast Corp. 2757
 Coloplast Corp. 3154
 Coloplast Corp. 453
 Combat Medical Ltd. 1026
 CommonSpirit Health 2152
 CompHealth 671
 Confederación Americana de Urología 1070
 Convergent Genomics 914, 2262
 Convergent Laser Technologies 1027
 Cook Medical 459
 Copper Medical Technology Co., Ltd 1069
 Coronis Health 2934
 CS Surgical, Inc 1948
 Curium 2825
 Decipher Urologic Cancers, Subsidiary of Veracyte 607
 Deep Bio 1015
 Dendreon Pharmaceuticals LLC 1235
 Designs for Vision, Inc. 1117
 Dornier MedTech 943, 2863
 DrTalks 2823
 Dyne Medical Group Inc. 2323
 Earned Wealth 2048
 ec2 Software Solutions 2448
 Ecleris USA 822
 ECU Health 2354
 Edgecare 1850
 Egyptian Urological Association 967
 Eigen Health 2043

Electro Medical Systems SA 669
 Eli Lilly 3164
 Elidah 2727
 ELMED Medical Systems 142
 Elsevier 717
 Empower Pharmacy 2326
 Endo Pharmaceuticals 1643
 Endourological Society, Inc. 1763
 Epic Physician Staffing 2733
 Erlanger Health 876
 Ethicon 1963
 Ethicon 2060
 European Association of Urology 1058
 Exelixis, Inc. 931
 Exosome Diagnostics 613
 EziSurg Medical 2832
 Farco Pharma 116
 Fellow 1750
 Ferring Pharmaceuticals Inc. 201, ExpoSuite 4, 6, 8
 Firefly Global 766
 FirmTech 2355
 Flume Catheter Company 765
 Focal Healthcare, Inc. 1727
 Focal One 409, 3043
 Focalyx 1635
 Foundation Medicine 110
 Fox Chase Temple Urologic Institute 1852
 Francis Medical 2359
 Freedom+ PFM - RESTORE CONTINENCE 1829
 Fujifilm Healthcare 353
 Gemini Medical Technologies 851
 GOTEK Medical USA LLC 1925
 Gimmi GmbH 2452
 Global Medical Endoscopy 1127
 GoPath Diagnostics 823
 GOTOP Medical, Inc. 567
 GRAIL 1162
 Guangzhou Potent Medical Equipment Joint-Stock Co., Ltd 1107
 Guangzhou Red Pine Medical Instrument Co., Ltd 1007
 Guerbet, LLC 907



ExpoSuites

ExpoSuites

Bioskills Hub

Robotics Theater

Food Court

Map showing booth locations for ExpoSuites, Bioskills Hub, Robotics Theater, and Food Court. Includes icons for equipment staging, didactic space, skills enhancement workshop, and food service.

SH MEDICAL CORP 812	United Endoscopy 1112
Shenzhen Besdata Technology Co.,Ltd ... 2848	United Medical Systems..... 1033
Siemens Healthineers 467	United Urology Group 270
Signati Medical, Inc 216	Universal Health Services (UHS) 2223
Sociedad Argentina de Urología..... 1068	University Compounding Pharmacy..... 2143
Sociedad Mexicana de urología 1062	Up Capital Management 2731
Sociedade Brasileira de Urologia (SBU)..... 959	Ur24Technology, Inc 310
Société Internationale d'Urologie (SIU)..... 1955	URO-1, Inc 1653
Society of Government Service Urologists (SGSU)..... 1761	UroGen Pharma, Inc. 1525, 2260
Society of Urologic Nurses and Associates (SUNA) 2053	Urologic Association of Asia..... 969
SoftWaveTRT..... 2935	Urological Society of India 965
Sonablate Corp 742, 1961	Urology Health Store 2349
SonoMotion, Inc. 1222	Urology Times 1828
Sontec Instruments..... 816	UrologyLocums.com 1655
Soundable Health..... 132	Uromedica, Inc. 824
Southeastern Section of the AUA, Inc./ Northeastern Section of the AUA, Inc. 1860	UroMems, Inc. 2570
Specialty Networks, LLC 2959	UroViu Corporation 1351, 1863
SpectraCure AB 1661	US Army Healthcare Recruiting 2750
SRS Medical Corp. 1535	US Navy Medical Recruiting 2844
St. Claire HealthCare 2828	Valar Labs Inc..... 2761
St. Luke's University Health Network 2255	Valencia Technologies..... 1822
STERIS Corporation 316	Vascular Technology 2243
Strauss Surgical / American Medical Endoscopy..... 1151	VasectomyStore.com 2449
Stream Dx 2729	Veradigm 2248
Stryker 212, 2758	Verana Health 1065
Sumitomo Pharma America, Inc. 1405, 1415, 2371	Verathon 1958
SUN Pharma 1751	Veterans Health Administration 2150
Surgical Science 2327	Veterans Prostate Cancer..... 1964
SURGIPROS LLC 2749	Viomerse 865
SurgiTel 2222	Vital Interaction..... 1125
Suture Ease, Inc. 2428	viv clinic 2747
Suzhou PeakSonic Medical Technology Co.,Ltd 2154	Wasatch Medical Specialties 2051
SZ HugeMed MED TECH DEV CO., LTD..... 1711	Watson Clinic, LLP 2450
Teleflex Interventional Urology... 1223, 2659	Weatherby Healthcare 2348
Telix Pharmaceuticals (US), Inc. 631, 2063	Well Lead Medical Co. Ltd. 1943
Tempus 1949	Wellnext 2454
Teradek 1071	Wellstar Health System 2548
The Gideons International..... 146	Western Section American Urological Association Inc (WSAUA) 1759
The Permanent Medical Group 678	WIN 2652
Theralase Technologies 771	WonderPax 2742
Theralogix 1851	XEOS 2225
Timm Medical 2754	Xialla Inc 778
TMC Health 2551	Xi'an Blueray Medical Technologies, Ltd. 2251
Tolmar Inc 322	Xuzhou Kaixin Electronic Instrument Co., Ltd..... 868
TTG Imaging Solutions 2153	Yigao Medical technology Co.,Ltd. 878
UC-CARE 1059	Zenflow, Inc. 2162
UFM Underwear for Men..... 672	Zhejiang Chuangxiang Medical Technology Co.,Ltd 966
	Zimmer MedizinSystems 1164

Halozyyme Therapeutics 2746	MacroLux Medical Technology Co., Ltd... 230
Hangzhou Hawk Optical Electronic Instruments Co.,Ltd 962	Male From Home..... 1928
HAPPINESS WORKS MEDICAL 2845	McLeod Health..... 2643
Hayes Locums 668	Mcube Technology Co., Ltd. 713
Health Best International LLC 1926	Mcubehealth 1133
HealthTrackRx 2451	Med Fibers, Inc. 759
HealthTronics, Inc. 2023	Meda Co., LTD 815
HistoSonics 1717, 2158	Medical Expo Supplies..... 2553
Holston Medical Group..... 2054	Medicus Healthcare Solutions..... 769
Houston Omics Collaborative..... 775	Medifix Inc 1754
HR HealthCare 222	MEDIFLEX 1823
Huger Medical Instrument Co. Ltd..... 666	Mediplus 1022
Hunan Vathin Medical Instrument Co.,Ltd..... 2127	Medispec 918
Huons USA..... 2655	Medpro 210, 2228
ID Medical Devices 2350	MedSol 964
ImmunityBio, Inc. 1931	MedTech International Group 134
Indiana University Kelley School of Business..... 130	MedTecX..... 776
Infinitus Medical Technologies 744	Medtronic 2543
Innovex Medical..... 864	Mendaera 2471
Integra LifeSciences 2026	MenHealth 2936
Intermountain Health 2149	menMD 773
Intuitive Surgical 2333, 2859	Merck & Co., Inc. 830, 3047, 3058, 3060
Invitae 1013	Microsurgery Instruments Inc..... 772
Irrisepit 1214	Mid-Atlantic Section of the AUA 1864
ISM Saddles, LLC 872	MIM Software Inc..... 1251
IsoPSA 1113	Minze Health..... 2226
IUmed 2426	Modernizing Medicine..... 1023
Japanese Urological Association 971	Modulight Corporation 1166
JenaSurgical by Asclepion Laser Technologies GmbH..... 2249	MoKan 2944
Jiangsu Sanwe Medical Science and Technology Co.,Ltd..... 677	Molecular Testing Labs 2424
JIASHAN HONGFENG 2843	Moonstone Nutrition 968
Johnson & Johnson 1443, 3045, 3161, 3165	Multiphze LLC 863
Kaneka North America, LLC 2649	Myriad Genetics 1725
KARL STORZ United States 401	MysteryVibe 2653
Kerecis 136	Neomedic International 977
Know Error 2647	NEOSCOPE2020 170
Koelis 951, 1962	New York Section Of The American Urological Association Inc 1765
Laborie Medical Technologies 1423, 2265	NextMed 1617
Lantheus 1205, 2365	NinoMed 2343
Larc Robotics 2324	Nonagen Bioscience Corp..... 2837
Lazarus 3D 217	North Central Section of the AUA, Inc./ South Central Section of the AUA, Inc. 1858
Lehigh Valley Health Network 2224	Northwell Health 213
Levee Medical, Inc. 2258	Novartis Pharmaceuticals Corporation 1555, 1865, 2059
LEXION Medical 2745	Novo Nordisk Health 475, 2559
LINA Medical 665	Novoglan Phimosiis Treatments 171
LithoLyte 659	NuCare Medical Solutions 2735
LocumTenens.com 1212	Ohio Valley Healthcare Solutions, LLC. 2751
LP Surgical Fibers 575	Olympus America Inc. 311
LSI SOLUTIONS 2227	Olympus America Inc. 3155, 3157
LynxDx 801	OMNIMEDICAL 674
	omo.md 1827

Opheras A/S 1760	Oruba Technology & Innovation 764
OTU Medical Inc 1923	Owensboro Health Medical Group 675
Pacific Edge Diagnostics USA Ltd ... 1158, 2058	Parker Laboratories, Inc. 2829
Pathnostics 1849	PathomIQ Inc. 1826
PathRight Medical 1953	PathRight Medical 1953
PD Labs 2645	Perineologic 2233
Perineologic 2233	Peruvian Society of Urology 963
Pfizer Oncology 443, 2259, 2360	PhalloFILL® 2555
PhalloFILL® 2555	Philips 1629
Photocure 601, 2159	Piedmont Healthcare 2253
Piedmont Healthcare 2253	Platform Innovations 2422
Porter Instrument 2049	PracticeLink 2252
Practis 2549	Presbyterian Healthcare Services 673
Presbyterian Healthcare Services 673	Prisma Health..... 2151
Prisma Health..... 2151	Precept Biorobotics 1429, 1859, 1960
Precept Biorobotics 1429, 1859, 1960	Profound Medical 623
Profound Medical 623	Promaxo 423
Promaxo 423	Prometheus Group, The 1611
Prometheus Group, The 1611	Promis Dx 2833
Promis Dx 2833	Promptly Patient Experience Suite 2928
Promptly Patient Experience Suite 2928	Prostatype Genomics Inc 817
Prostatype Genomics Inc 817	Protara Therapeutics Inc. 870
Protara Therapeutics Inc. 870	Provepharm 1825
Provepharm 1825	Provider Solutions & Development 2850
Provider Solutions & Development 2850	Pusen Medical..... 913
Pusen Medical..... 913	Q-Optics & Quality Aspirators Inc. 2148
Q-Optics & Quality Aspirators Inc. 2148	QUAD A 2846
QUAD A 2846	Quanta System SPA 1143
Quanta System SPA 1143	Quest Healthcare Solutions..... 577
Quest Healthcare Solutions..... 577	RetroPerc, Inc. 1758
RetroPerc, Inc. 1758	Revelation Pharma 2748
Revelation Pharma 2748	RG Medical 725
RG Medical 725	Richard Wolf Medical Instruments Corporation 211, 301
Richard Wolf Medical Instruments Corporation 211, 301	Rigicon A.S. 777
Rigicon A.S. 777	Ris 1854
Ris 1854	Rocamed 471
Rocamed 471	Rose Micro Solutions LLC 723, 1723
Rose Micro Solutions LLC 723, 1723	RosmanSearch 1755
RosmanSearch 1755	Russer 151
Russer 151	Sagent Urology 927
Sagent Urology 927	Sagis Diagnostics 2831
Sagis Diagnostics 2831	Sapayen..... 2351
Sapayen..... 2351	Scivita Medical Technology Co., Ltd. 2022
Scivita Medical Technology Co., Ltd. 2022	SEEGEN ENDOSCOPY..... 215
SEEGEN ENDOSCOPY..... 215	Seplou Medical 859

GOLDSTEIN MICROSPIKE™ BOOTH #1123

Approximator Clamps for Vasovasostomy and Vasoepididymostomy

- Ends clamp slippage.
- Will not damage mucosa.
- Can be adjusted and locked in any position.
- Folds in two directions to facilitate anterior and posterior wall anastomoses.
- Can be stabilized by attaching a hemostat or needle holder.

NOTE: Both gripping surfaces have four flat-tipped stainless steel spikes to grip adventitia securely without mucosal damage.

Marc Goldstein, MD, DSc (hon), FACS, Matthew P. Hardy Distinguished Professor of Reproductive Medicine and Urology Senior Scientist, Population Council Surgeon-in-Chief, Male Reproductive Medicine and Surgery Cornell Institute for Reproductive Medicine Weill Cornell Medical College of Cornell University New York-Presbyterian Hospital/Weill Cornell Medical Center

assi ACCURATE SURGICAL & SCIENTIFIC INSTRUMENTS® For diamond perfect performance®

accurate surgical & scientific instruments corporation
800.645.3569 • 516.333.2570 • fax: 516.997.4948
west coast: 800.255.9378 • Info: assi@accuratesurgical.com
Orders: orders@accuratesurgical.com www.accuratesurgical.com

Not all ASSI products shown in our literature or on our website are available for sale in Canada

VOICES & VIEWS

Join the Conversation on Instagram, facebook, and X. #AUA24   

QUESTION OF THE DAY

How are you promoting diversity, equity, inclusion and accessibility in the workplace and/or in urology?

In Japan, we are trying to increase the ratio of female professors and female urologists by creating a structure that encourages their involvement. Urology is one of the most male-dominated specialties, and we want to change that situation.



Eisuke Tomiyama, MD, PhD
Vancouver, BC, Canada

I am the chair of the Community Prostate Health Fair, which started last year as an annual event with R. Frank Jones (Urological Society) and some other partners, including the American Medical Association. Essentially, we go to conferences and into communities to do free PSA screenings and we connect people with resources outside of their community, whether that is with the American Cancer Society or health equity funds like Zero Prostate. We believe education is important, and we also think that longitudinal relationships are important. By linking those communities not only with those resources outside, but with research institutions or hospitals within their community and striking those relationships, we think we can make a difference in health disparities.



John McGill, MD
Leesburg, Georgia

Urology, as a community, is seeing such a huge demand for the limited supply of urologists, and there absolutely is an active approach that starts even with the medical student and even college student to try to influence those young people toward a path in urology. There are only 12,000-13,000 practicing urologists in the United States, and we want to create as much diversity for our patients as possible, whether it's in clinical research trials or in clinical practice. We have to engage in technology, support staff and get more residents with GMA funding, which are some of the strategies we are using. I am a Korean-American, and I am very proud of the pathway the AUA as an organization has provided me.



Eugene Rhee, MD, MBA
San Diego, California

Scan the QR code for a preview of today's session, "A remedy worth fighting for."




Francesca Monn
@MFrancescaMD
Proud of our own, Dr Jenks
@SIU_URO_RES representing NCS in the resident bowl for #AUA24



Justin Badal, MD
@JustinBadal
Dr. Lerner presenting his S1011 data at #AUA24. An absolutely Herculean effort to understand ELND vs SLND in #MIBC. #SUO #SWOG @bcm_urology



Amy Pearlman, MD
@AmyPearlman1
You know you're sharing a hotel room with a pelvic floor physical therapist when you walk into the hotel room and this is the first thing you see...
@AmerUrological
#AUA24 - why did she bring these items? You'll have to attend our ball pain course on Saturday to find out!



Sarah P. Psutka MD, MS
@spsutkaMD
Congratulations to our best poster winner in the Advanced Kidney cancer session this morning! Drs. Mark Dawidek, Stephen Reese @arihakimi and team!
#AUA24 #MSKCC




Kristian Stensland, MD, MPH
@stensy
Prostate cancer clinical trials infrequently use patient-centered outcomes, but it doesn't seem associated with enrollment. Outstanding presentation from amazing resident and future SUO applicant Madison Krischak!
@MadisonKrischak
@UMichUrology #AUA24



Dave Penson
@urogeek
Pilot poster format at #AUA24. "Walking tours" of the posters. Check out this new format in room 301b throughout the meeting and let me know what you think. I hope to make the meeting more interactive, educational and entertaining

Does looking for
Prostate Cancer
feel like finding a

needle in a haystack?



SUREcore with coreCARE



Standard of care

The SUREcore needle provides significantly more tissue volume, length and quality.



Consistently
**bigger,
better, longer
cores**

from the
SUREcore™ Needle
and coreCARE™



Visit us during
AUA2024
Booth # 1653



AUA2024
San Antonio, TX
May 3-5, 2024

www.uro1medical.com

LithoVue™ Elite

Single-Use Digital Flexible Ureteroscope System
with intrarenal pressure monitoring



Know more
Accurate, real-time IRP monitoring



**Make informed, real-time pressure-related clinical decisions
with the first ureteroscope with intrarenal pressure monitoring.**



**See more, know more, and do more with the
LithoVue Elite System. Visit us at booth 431.**